Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
[This corrects the article DOI: 10.1371/journal.pgen.1000832.].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955517 | PMC |
| http://dx.doi.org/10.1371/journal.pgen.1007392 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Exploring the biomechanical complexity of glioblastoma spheroids and organoids with co-localized Brillouin and Raman microspectroscopy.
Biochem Biophys Rep
December 2025
Department of Neurosurgery, Faculty of Medicine and University Hospital Carl Gustav Carus, TU Dresden, Dresden, Germany.
Brillouin microscopy allows mechanical investigations of biological materials at the subcellular level and can be integrated with Raman spectroscopy for simultaneous chemical mapping, thus enabling a more comprehensive interpretation of biomechanics. The present study investigates different in vitro glioblastoma models using a combination of Brillouin and Raman microspectroscopy. Spheroids of the U87-MG cell line and two patient-derived cell lines as well as patient-derived organoids were used.
View Article and Find Full Text PDFSynthesis, Radiolabeling, and Evaluation of a Dimeric Fibroblast Activation Protein Inhibitor with a Triazine Linker.
Mol Pharm
September 2025
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Dimeric fibroblast activation protein inhibitor (FAPI) radioligands are promising candidates for theranostic applications because of their enhanced tumor uptake and prolonged retention compared to monomeric radioligands. Several linker strategies have been investigated to connect two FAPI motifs and a radiometal chelator in a dimer design. In this study, we report the development of a novel dimeric FAPI radioligand, [Ga]Ga-, which utilizes a triazine core as a trifunctional linker.
View Article and Find Full Text PDFEvaluation of the PP6D5 Polymer as a Novel Non-Viral Vector in the Development of a CRISPR/nCas9-Based Gene Therapy for Tay-Sachs Disease.
Pharmaceutics
May 2025
Institute for the Study of Inborn Errors of Metabolism, Faculty of Science, Pontificia Universidad Javeriana, Bogotá D.C. 110231, Colombia.
Tay-Sachs disease (TSD) is a neurodegenerative disorder caused by a deficiency in β-hexosaminidase A (HexA), which accumulates GM2 gangliosides, primarily in neurons. Currently, therapeutic options are limited, highlighting the need for new strategies such as gene therapy. Despite their effectiveness, viral vectors can elicit adverse immune responses; consequently, non-viral vectors are being explored as an alternative.
View Article and Find Full Text PDFComparative Study of Dimeric Fibroblast Activation Protein-Targeting Radioligands Labeled with Fluorine-18, Copper-64, and Gallium-68.
Mol Pharm
February 2025
Department of Nuclear Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Fibroblast activation protein inhibitors (FAPIs) labeled with gallium-68 and lutetium-177 show potential for use in the diagnosis and treatment of various cancers expressing FAP. However, Lu-labeled FAPIs often exhibit short tumor retention time, limiting their therapeutic applications. To improve tumor retention, we synthesized three radiolabeled dimeric FAPIs, [F], [Cu], and [Ga].
View Article and Find Full Text PDFSynthesis and Preclinical Evaluation of a Novel Fluorine-18-Labeled Tracer for Positron Emission Tomography Imaging of Bruton's Tyrosine Kinase.
ACS Pharmacol Transl Sci
March 2023
Center for Advanced Study of Drug Action and Department of Chemistry, Stony Brook University, John S. Toll Drive, Stony Brook, New York 11794-3400, United States.
Bruton's tyrosine kinase (BTK) is a target for treating B-cell malignancies and autoimmune diseases. To aid in the discovery and development of BTK inhibitors and improve clinical diagnoses, we have developed a positron emission tomography (PET) radiotracer based on a selective BTK inhibitor, remibrutinib. [F]PTBTK3 is an aromatic, F-labeled tracer that was synthesized in 3 steps with a 14.
View Article and Find Full Text PDF